In this episode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including recent approvals from the House Energy and Commerce Subcommittee on Health and Phase 3 clinical trial results for oral semaglutide to treat obesity.
Podcast Tags: healthcare, healthcare news, health plans, life sciences, health policy, public health, Medicare, drug prices, PBMs, 340B, obesity
Source Links:
- A key House panel approved a slew of health policies. Here’s a look at 4 of them
- Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
- Anti-obesity medications are set to skyrocket this year. But how will we afford them?
- What Could New Anti-Obesity Drugs Mean for Medicare?
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
Mindy McGrath, Healthcare Industry Advisor and Head of Public Health Sector
Ryan Hummel, Executive and Head of Provider Sector
Jen Burke, Healthcare Industry Strategist
Previous Podcast
25 May 2023
MedTech Goes Digital
Listen now
Speed to publication with GenAI: Done the right way
In the last three years, Generative AI (GenAI) has moved from novelty to expectation. Across industries, teams are being asked, whether explicitly or
Read moreInizio Ignite Sparks a New Era of Connected Advisory Solutions
Inizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM.
Read moreASH® 2025 roundtable: Turning hematology innovation into real world progress
Insights from ASH® 2025 on hematology innovation, CAR-T, bispecifics, diagnostics, and how connected strategy supports real-world adoption.
Read more